Abnormal Uterine Bleeding

Etiology and Evaluation of Abnormal Uterine Bleeding

BEFORE MENARCHE

Malignancy, trauma, and sexual abuse or assault are potential causes of abnormal uterine bleeding before menarche. A pelvic examination (possibly under anesthesia) should be performed, because a reported 54 percent of cases involve focal lesions of the genital tract, and 21 percent of these lesions may be malignant.3

CHILDBEARING YEARS

The menstrual cycle has three phases. During the follicular phase, follicle-stimulating hormone levels increase, causing a dominant follicle to mature and produce estrogen in the granulosa cells. With estrogen elevation, menstrual flow ceases, the endometrium proliferates, and positive feedback is exerted on luteinizing hormone (LH), resulting in the ovulatory phase. During the luteal phase, progesterone elevation halts proliferation of the endometrium and promotes its differentiation; progesterone production by the corpus luteum diminishes, causing endometrial shedding, or menstruation. A menstrual cycle of fewer than 21 days or more than 35 days or a menstrual flow of fewer than two days or more than seven days is considered abnormal.6 (pp201–38)

Pregnancy is the first consideration in women of childbearing age who present with abnormal uterine bleeding (Table 1).7,8 Potential causes of pregnancy-related bleeding include spontaneous pregnancy loss (miscarriage), ectopic pregnancy, placenta previa, abruptio placentae, and trophoblastic disease. Patients should be questioned about cycle patterns, contraception, and sexual activity. A bimanual pelvic examination (seeking uterine enlargement), a beta-subunit human chorionic gonadotropin test, and pelvic ultrasonography are useful in establishing or ruling out pregnancy and pregnancy-related disorders.

Next, iatrogenic causes of abnormal uterine bleeding should be explored. Bleeding may be induced by medications, including anticoagulants, selective serotonin reuptake inhibitors, antipsychotics, corticosteroids, hormonal medications, and tamoxifen (Nolvadex). Herbal substances, including ginseng, ginkgo, and soy supplements, may cause menstrual irregularities by altering estrogen levels or clotting parameters.9

Once pregnancy and iatrogenic causes have been excluded, patients should be evaluated for systemic disorders, particularly thyroid, hematologic, hepatic, adrenal, pituitary, and hypothalamic conditions (Table 2). Menstrual irregularities are associated with both hypothyroidism (23.4 percent of cases) and hyperthyroidism (21.5 percent of cases).10 [Strength of recommendation (SOR) B. Consistent cohort studies] Thyroid function tests may help the physician determine the etiology.

Inherited coagulopathy has been shown to be the underlying cause of abnormal uterine bleeding in 18 percent of white women and 7 percent of black women with menorrhagia.11 These patients may present in adolescence with severe menstrual bleeding or frequent bruising. A complete blood count with platelet count should be obtained. If a coagulation defect is suspected, consultation with a hematologist may be the most cost-effective option in the absence of reasonable screening tests for specific abnormalities.11 Because jaundice and hepatomegaly may suggest underlying acquired coagulopathy, liver function tests should be considered.

Obesity, acne, hirsutism, and acanthosis nigricans may be signs of polycystic ovary syndrome or diabetes mellitus. Polycystic ovary syndrome is associated with unopposed estrogen stimulation, elevated androgen lev els, and insulin resistance, and is a common cause of anovulation.6(p499),12

The presence of galactorrhea, as determined by the history or physical examination, may indicate underlying hyperprolactinemia, which can cause oligoovulation or eventual amenorrhea. A prolactin level confirms the diagnosis of hyperprolactinemia. Hypothalamic suppression secondary to eating disorders, stress, or excessive exercise may induce anovulation, which sometimes manifests as irregular and heavy menstrual bleeding or amenorrhea.

Genital tract pathology may be associated with intermenstrual, postcoital, and heavy menstrual bleeding.4 Any history of abnormal Papanicolaou (Pap) smears, sexually transmitted disease, gynecologic surgery, trauma, or sexual abuse should be elicited. Uterine fibroids, endometrial polyps, adenomyosis, endometrial hyperplasia and atypia, and endometrial cancer should be excluded.13

The evaluation of postmenarchal women who present with abnormal uterine bleeding includes a pelvic examination, as well as a Pap smear if appropriate, to look for vulvar or vaginal lesions, signs of trauma, and cervical polyps or dysplasia. Cervical dysplasia seldom causes abnormal uterine bleeding, but it may be associated with postcoital bleeding.14 Cervical cultures may be indicated if the patient is at risk for infection or if symptoms of infection are present. A bimanual examination in the postmenarchal woman may reveal tenderness associated with infection, an adnexal mass consistent with an ovarian neoplasm or cyst, or uterine enlargement consistent with fibroids, pregnancy, or a tumor.

Because endometrial abnormalities are present in 31 percent of patients with a Pap result of “atypical glandular cells of undetermined significance, favor endometrial origin,” endometrial biopsy is indicated.15 [SOR B, observational studies] Transvaginal ultrasonography may be useful in delineating the underlying cause of abnormal uterine bleeding that is associated with uterine enlargement or an adnexal mass. Even if the pelvic examination is normal, further evaluation of the endometrium may be required to eliminate less obvious abnormalities.

Dysfunctional uterine bleeding, with both anovulatory and, less commonly, ovulatory4 causes, occurs during the childbearing years. It is a diagnosis of exclusion and is made only after pregnancy, iatrogenic causes, systemic conditions, and obvious genital tract pathology have been ruled out (Figure 1).2,16

Anovulatory dysfunctional uterine bleeding is a disturbance of the hypothalamic-pituitary-ovarian axis that results in irregular, prolonged, and sometimes heavy menstrual bleeding. It may occur immediately after menarche but before maturation of the hypothalamic-pituitary-ovarian axis, or it may occur during perimenopause, when declining estrogen levels fail to regularly stimulate the LH surge and resulting ovulation.

Unopposed estrogen stimulation may lead to endometrial proliferation and hyperplasia. Without sufficient progesterone to stabilize and differentiate the endometrium, this mucous membrane becomes fragile and sloughs irregularly. Estrogen also affects uterine vascular tone, angiogenesis, prostaglandin formation, and endometrial nitric oxide production.4

Ovulatory dysfunctional bleeding may include polymenorrhea, oligomenorrhea, midcycle spotting, and menorrhagia (Table 3).6 (pp575-9) Polymenorrhea, a presumed lutealphase dysfunction, results in shortened cycles (less than 21 days), whereas oligomenorrhea, a prolonged follicular-phase dysfunction, results in lengthened cycles (more than 35 days). Mid-cycle spotting occurs before ovulation as the estrogen levels decline.6 Menorrhagia is regularly occurring heavy menstrual bleeding (more than 80 mL per cycle) and may result from the loss of local endometrial hemostasis.

View/Print Figure

Abnormal Uterine Bleeding in Women of Childbearing Age

FIGURE 1.

Sequential steps through the differential diagnosis of abnormal uterine bleeding in women of childbearing age.

Information from references 2 and 16.

Abnormal Uterine Bleeding in Women of Childbearing Age

---

FIGURE 1.

Sequential steps through the differential diagnosis of abnormal uterine bleeding in women of childbearing age.

Information from references 2 and 16.

Further Evaluation Based on Risk Factors for Endometrial Cancer

Further evaluation of abnormal uterine bleeding depends on the patient's age and the presence of risk factors for endometrial cancer, which include anovulatory cycles, obesity, nulliparity, age greater than 35 years, and tamoxifen therapy.17,18 Initially, medical management is recommended for premenopausal women at low risk for endometrial carcinoma who are diagnosed with presumed dysfunctional uterine bleeding.

Diabetes is a demonstrated risk factor for endometrial cancer.17 Women with long or irregular cycles are at risk for developing type 2 diabetes and therefore should undergo diabetes screening.19

Endometrial cancer is rare in 15- to 18-year-old females.18 Therefore, most adolescents with dysfunctional uterine bleeding can be treated safely with hormone therapy and observation, without diagnostic testing.20

The risk of developing endometrial cancer increases with age.18 The overall incidence of this cancer is 10.2 cases per 100,000 in women aged 19 to 39 years. The incidence more than doubles from 2.8 cases per 100,000 in those aged 30 to 34 years to 6.1 cases per 100,000 in those aged 35 to 39 years. In women aged 40 to 49 years, the incidence of endometrial carcinoma is 36.5 cases per 100,000. Thus, the American College of Obstetricians and Gynecologists recommends endometrial evaluation in women aged 35 years and older who have abnormal uterine bleeding.21 [SOR C, consensus guideline]

Endometrial evaluation (including imaging and tissue sampling) for subtle genital tract pathology is recommended in patients who are at high risk for endometrial cancer and in patients at low risk who continue bleeding abnormally despite medical management.21

Imaging and Tissue Sampling

The sensitivity of endometrial biopsy for the detection of endometrial abnormalities has been reported to be as high as 96 percent.22 However, this office-based procedure may miss up to 18 percent of focal lesions,23 including polyps and fibroids, because only a small part of the endometrium may be sampled at any one time. Although endometrial biopsy has high sensitivity for endometrial carcinoma,24,25 its sensitivity for detecting atypical endometrial hyperplasia may be as low as 81 percent.25 [Reference 25: SOR B, meta-analysis of lower quality/inconsistent studies]

Transvaginal ultrasonography may reveal leiomyoma, endometrial thickening, or focal masses. Although this imaging modality may miss endometrial polyps and submucous fibroids, it is highly sensitive for the detection of endometrial cancer (96 percent) and endometrial abnormality (92 percent).26 [SOR A, meta-analysis of consistent, good-quality studies] Compared with dilatation and curettage, endometrial evaluation with transvaginal ultrasonography misses 4 percent more cancers,26,27 but it may be the most cost-effective initial test in women at low risk for endometrial cancer who have abnormal uterine bleeding that does not respond to medical management.28

Saline-infusion sonohysterography bolsters the diagnostic power of transvaginal ultrasonography. This technique entails ultrasound visualization after 5 to 10 mL of sterile saline has been instilled in the endometrial cavity. Its sensitivity and specificity for endometrial cancer are comparable with the high sensitivity and specificity of diagnostic hysteroscopy.29 [SOR B, meta-analysis with significant heterogeneity] Saline-infusion sonohysterography is more accurate than transvaginal ultrasonography in diagnosing intracavitary lesions30,31 and is more accurate than hysteroscopy in diagnosing endometrial hyperplasia.32 The ombination of directed endometrial biopsy and saline-infusion sonohysterography results in a sensitivity of 95 to 97 percent and a specificity of 70 to 98 percent for the identification of endometrial abnormality.33,34 [References 33 and 34: SOR B, diagnostic cohort studies]

Although dilatation and curettage has been the gold standard for diagnosing endometrial cancer,35 it no longer is considered to be therapeutic for abnormal uterine bleeding; furthermore, it is limited in its ability to access the tubal cornua of the uterus.36 Hysteroscopy with biopsy provides more information than dilatation and curettage alone37 and rivals the combination of saline-infusion sonohysterography and endometrial biopsy in its ability to diagnose polyps, submucous fibroids, and other sources of abnormal uterine bleeding.31

Postmenopausal women with abnormal uterine bleeding, including those who have been receiving hormone therapy for more than 12 months, should be offered dilatation and curettage for evaluation of the endometrium (96 percent sensitivity for the detection of cancer, with a 2 to 6 percent false-negative rate).26 Postmenopausal women who are poor candidates for general anesthesia and those who decline dilatation and curettage may be offered transvaginal ultrasonography or saline-infusion sonohysterography with endometrial biopsy.

Further research is necessary to determine the best method for evaluating the endometrium in patients with abnormal uterine bleeding. However, based on current evidence, saline-infusion sonohysterography with endometrial biopsy appears to provide the most complete evaluation with the least risk33,34 (Figures 223,26,38 and 3).

Medical Management

ANOVULATORY DYSFUNCTIONAL UTERINE BLEEDING

Oral contraceptive pills (OCPs) are used for cycle regulation and contraception. In patients with irregular cycles secondary to chronic anovulation or oligoovulation, OCPs help to prevent the risks associated with prolonged unopposed estrogen stimulation of the endometrium. OCPs effectively manage anovulatory bleeding in premenopausal and perimenopausal women. Treatment with cyclic progestins for five to 12 days per month is preferred when OCP use is contraindicated, such as in smokers over age 35 and women at risk for thromboembolism21  (Table 4).16,39,40

View/Print Figure

Presumed Dysfunctional Uterine Bleeding in Women of Childbearing Age: Evaluation Based on Risk Factors for Endometrial Cancer

FIGURE 2.

Evaluation of women of childbearing age with presumed dysfunctional uterine bleeding, based on risk for endometrial cancer.

Presumed Dysfunctional Uterine Bleeding in Women of Childbearing Age: Evaluation Based on Risk Factors for Endometrial Cancer

---

FIGURE 2.

Evaluation of women of childbearing age with presumed dysfunctional uterine bleeding, based on risk for endometrial cancer.

OVULATORY DYSFUNCTIONAL UTERINE BLEEDING

Medical therapy for menorrhagia primarily includes nonsteroidal anti-inflammatory drugs (NSAIDs) and the levonorgestrel releasing intrauterine system (Mirena). The U.S. Food and Drug Administration has approved the use of mefenamic acid (Ponstel), an NSAID, for the treatment for menorrhagia; this agent is well tolerated.41 [SOR A, meta-analysis] The levonorgestrel contraceptive device has been shown to decrease menstrual blood loss significantly and to be superior to cyclic progestins for this purpose.42 [SOR A, meta-analysis]

View/Print Figure

Abnormal Uterine Bleeding in Postmenopausal Women

FIGURE 3.

Evaluation of abnormal uterine bleeding in postmenopausal women.

Abnormal Uterine Bleeding in Postmenopausal Women

---

FIGURE 3.

Evaluation of abnormal uterine bleeding in postmenopausal women.

Although the effect of OCPs on menorrhagia has not been well studied, one small randomized trial comparing OCPs, mefenamic acid, naproxen, and danazol showed no significant difference in their effectiveness in treating menorrhagia.43 [SOR B, single randomized controlled trial] Side effects and cost limit the use of androgens such as danazol and gonadotropin-releasing hormone agonists in the treatment of menorrhagia, but these agents may be used for short-term endometrial thinning before ablation is performed.44 [SOR A, meta-analysis]

Antifibrinolytics significantly reduce heavy menstrual bleeding. However, these agents are used infrequently because of concerns about safety (i.e., potential for thromboembolism).45

Intravenous administration of conjugated estrogens (Premarin) may be required in women with acute uterine hemorrhage.40 [SOR B, single randomized controlled study]

Surgical Management

When medical therapy fails or is contraindicated, surgical intervention may be required. Hysterectomy is the treatment of choice when adenocarcinoma is diagnosed, and this procedure also should be considered when biopsy specimens contain atypia.13  Hysterectomy and various uterus-sparing surgical procedures for the treatment of abnormal uterine bleeding are beyond the scope of this article but are listed in Table 5.